Skip to content

Study · Non-randomized trial · n = 3 · 2014

6 results

Beneficial effects of the melanocortin analogue Nle4-D-Phe7-α-MSH in acne vulgaris.

Böhm M, Ehrchen J, Luger TA

Journal of the European Academy of Dermatology and Venereology : JEADV27 Jul 2012Cited by 23 (Europe PMC)

PMID22845050 (opens in a new tab)DOI10.1111/j.1468-3083.2012.04658.x (opens in a new tab)PepBankPUB-22845050
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In three patients with mild-to-moderate facial acne vulgaris, the total lesion count declined in all patients 56 days after the first afamelanotide injection.

    In plain wordsIn three people with mild-to-moderate facial acne, the total number of acne lesions fell after afamelanotide, with no control group.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseTotal acne lesion count at day 56
    Study

    n = 3

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    16 mg · subcutaneous implantAs given in this study (human).

    Source sentences

    Summary
    The total number as well as the number of inflammatory acne lesions declined in all patients 56 days after the first injection of afamelanotide.
    1 context sentence
    Summary · context
    Afamelanotide (16 mg) was given in a phase II open-label pilot study subcutaneously as a sustained-release resorbable implant formulation to 3 patients with mild-to-moderate facial acne vulgaris.
  2. 02HumanNon-randomized trialEfficacy outcome

    In three patients with mild-to-moderate facial acne vulgaris, the number of inflammatory lesions declined in all patients 56 days after the first afamelanotide injection.

    In plain wordsIn three people with mild-to-moderate facial acne, the number of inflamed lesions fell after afamelanotide, with no control group.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseInflammatory acne lesion count at day 56
    Study

    n = 3

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    16 mg · subcutaneous implantAs given in this study (human).

    Source sentences

    Summary
    The total number as well as the number of inflammatory acne lesions declined in all patients 56 days after the first injection of afamelanotide.
    1 context sentence
    Summary · context
    Afamelanotide (16 mg) was given in a phase II open-label pilot study subcutaneously as a sustained-release resorbable implant formulation to 3 patients with mild-to-moderate facial acne vulgaris.
  3. 03HumanNon-randomized trialEfficacy outcome

    In three patients with mild-to-moderate facial acne vulgaris, Dermatology Life Quality Index scores improved in all patients 56 days after the first afamelanotide injection.

    In plain wordsIn three people with mild-to-moderate facial acne, quality of life scores improved after afamelanotide, with no control group.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Direction not reportedDermatology Life Quality Index at day 56
    Study

    n = 3

    Outcome group
    Quality of life · Skin and wound
    Studied dose
    16 mg · subcutaneous implantAs given in this study (human).

    Source sentences

    Summary
    Life quality as measured by Dermatology Life Quality Index likewise improved in all 3 patients 56 days after the first injection of afamelanotide.
    1 context sentence
    Summary · context
    Afamelanotide (16 mg) was given in a phase II open-label pilot study subcutaneously as a sustained-release resorbable implant formulation to 3 patients with mild-to-moderate facial acne vulgaris.
  4. 04HumanNon-randomized trialSafety outcome

    In three patients with acne vulgaris, afamelanotide caused no adverse effects except mild and short-term fatigue in one patient.

    In plain wordsIn three people with acne, afamelanotide caused no side effects except mild, short-lived tiredness in one person.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableAdverse effects
    Study

    n = 3

    Outcome group
    Adverse events · Whole body
    Studied dose
    16 mg · subcutaneous implantAs given in this study (human).

    Source sentences

    Summary
    There were no adverse effects except mild and short-term fatigue in one patient.
    1 context sentence
    Summary · context
    Afamelanotide (16 mg) was given in a phase II open-label pilot study subcutaneously as a sustained-release resorbable implant formulation to 3 patients with mild-to-moderate facial acne vulgaris.
  5. 05HumanNon-randomized trialEfficacy outcome

    In three patients with acne vulgaris, all patients experienced increased pigmentation after afamelanotide, especially on the face.

    In plain wordsIn three people with acne, skin pigmentation increased after afamelanotide, especially on the face.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    IncreaseSkin pigmentation
    Study

    n = 3

    Outcome group
    Pigmentation · Skin and wound
    Studied dose
    16 mg · subcutaneous implantAs given in this study (human).

    Source sentences

    Summary
    All patients experienced increased pigmentation especially on the face.
    1 context sentence
    Summary · context
    Afamelanotide (16 mg) was given in a phase II open-label pilot study subcutaneously as a sustained-release resorbable implant formulation to 3 patients with mild-to-moderate facial acne vulgaris.
  6. 06HumanNon-randomized trialSafety outcome

    In three patients with acne vulgaris, clinically relevant changes in laboratory parameters were not detected after afamelanotide.

    In plain wordsIn three people with acne, afamelanotide caused no clinically relevant changes in blood, urine, liver or kidney tests.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeLaboratory parameters (blood counts, electrolytes, urine, liver and kidney tests)
    Study

    n = 3

    Outcome group
    Adverse events · Whole body
    Studied dose
    16 mg · subcutaneous implantAs given in this study (human).

    Source sentences

    Summary
    Clinically relevant changes in laboratory parameters were not detected.
    2 context sentences
    Summary · context
    Monitoring of laboratory parameters included differential blood counts, electrolytes, urine analysis, and liver and kidney function tests.
    Summary · context
    Afamelanotide (16 mg) was given in a phase II open-label pilot study subcutaneously as a sustained-release resorbable implant formulation to 3 patients with mild-to-moderate facial acne vulgaris.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.